leisure time -WSS

leisure time

author：knowledge 2025-10-01 15:27:40 - browse：161

Kara Coluccio, a managing partner at Perspective Group poses for a portrait. -- health coverage from STAT — Kara Coluccio, a managing partner at Perspective Group, says the job market for biotech executives has gotten much tighter. Jessica Rinaldi/Globe Staff

When Crystal Shih Byers left her job at Novartis in 2020, she was excited to make the leap into a smaller startup.

Byers had spent almost nine years at Novartis, most recently helping lead a group that worked on gene therapy. But pharmaceutical companies are large and complex, and she craved more immediate impact. “I was looking for a place where I could be in the room,” she says. She wanted more autonomy, and to feel like her work would reach patients sooner.

At the time, biotech startups were rolling in cash and seeking to capture some of the magic that had fueled Moderna’s meteoric rise. They handed out lots of logo-embossed swag. “Investors were putting a lot of money into stupid science,” Byers says. “There were a lot of companies that lasted for a lot longer than I thought they would on very little data.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： In key trial, Verve's treatment lowers cholesterol levels in patients

hotspot

WSS

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Hospitals look to new technology to keep health care workers safe

World's first CRISPR

Primary care physicians play key roles in Alzheimer's management

Eliminate the waiting period for sterilization covered by Medicaid

A daunting task: navigating dual Medicare, Medicaid eligibility

focus

leisure time

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Supreme Court mifepristone arguments center on docs' right to sue

Supreme Court strikes down use of affirmative action

Ransomware attacks on hospitals: Study outlines patient impact

Medicare details structure of new drug price negotiation program

FDA's Woodcock to retire early next year

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Heart attack and stroke risk calculators need revising

Why the world’s most expensive drug might be worth the price

hotspot

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

CRISPR pioneers react to Casgevy, first gene

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Supreme Court mifepristone arguments center on docs' right to sue

Weight loss drug costs may need more research, senator suggests

Steward Health Care has deal to sell doctor network to UnitedHealth

hotspot

entertainment

hotspot

hotspot